ArriVent BioPharma, Inc.
USD33.19
+0.43 (+1.31%)
CEO
Zhengbin Yao
IPO Date
2024-01-26
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$32.59
Prev. Close
$32.76
Day Low
$31.61
Day High
$33.81
52W Low
$16.10
52W High
$35.83
Market Cap
$1.55B
Volume
0.83M
| 13,562 |
| $31.74 |
| 22 Jun 2026 | Hohneker John | director | A-Award | Acquired | 13,562 | $31.74 |
| 22 Jun 2026 | Nolet Chris | director | A-Award | Acquired | 13,562 | $31.74 |
| 4 Feb 2026 | LaChapelle Robin | Chief Operating Officer | A-Award | Acquired | 130,000 | $22.67 |
| 4 Feb 2026 | Lutzker Stuart | director, officer: President of R&D | A-Award | Acquired | 150,000 | $22.67 |
| 4 Feb 2026 | Kung Winston | Chief Financial Officer | A-Award | Acquired | 140,000 | $22.67 |
| 4 Feb 2026 | Yao Zhengbin | director, officer: President and CEO | A-Award | Acquired | 550,000 | $22.67 |
| 4 Feb 2026 | Kastenmayer James Paul | General Counsel | A-Award | Acquired | 130,000 | $22.67 |
| 3 Feb 2026 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | S-Sale | Disposed | 555,555 | $23.37 |